Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Pelage Pharmaceuticals Inc. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct examiners and various art units. This indicates that the company's current patent applications are being evaluated by different specialized groups within the patent office, which could lead to varied prosecution experiences. The presence of the 2 pending office actions across the various units suggests a diverse intellectual property strategy.
Rilla Marie Samsell is the busiest examiner for this portfolio, with 1 pending office action. Since there are several pending actions in total, the workload is split, with Rilla Marie Samsell handling 1 of the company's active office action responses. Practitioners should focus on the specific requirements of Rilla Marie Samsell, as her review of the action represents a significant portion of the company's current prosecution. The outcome of this case will be a key indicator of the company's success in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMSELL, RILLA MARIE | 1 | 69.1% | +6.4% |
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18013808 | COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH | FETTEROLF, BRANDON J | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18013808 | COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH | FETTEROLF, BRANDON J | 14d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18725732 | COMPOUNDS FOR TREATMENT OF HAIR LOSS | SAMSELL, RILLA MARIE | 1624 | §103§112DP | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18013808 | COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH | FETTEROLF, BRANDON J | 1626 | §103§112Other | Non-Final OA | 14d | Pending | Dec 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPelage Pharmaceuticals Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Rilla Marie Samsell has the most, with 1 of Pelage Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
